Last10K.com

Johnson Johnson (JNJ) SEC Filing 10-K Annual Report for the fiscal year ending Sunday, January 1, 2023

SEC Filings

JNJ Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

JNJ Annual Reports

JNJ Quarterly Reports

JNJ Corporate News

JNJ Merger Prospectus

Johnson Johnson

HISTORY TOOLS
CIK: 934796 Ticker: JNJ

Exhibit 99.1

JOHNSON & JOHNSON REPORTS 2022 FOURTH-QUARTER AND FULL YEAR RESULTS:
•2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%*

•2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%*

•2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%*

•2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 increasing by 3.6%*

•Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and adjusted operational EPS of $10.50, reflecting growth of 3.5%*


New Brunswick, N.J. (January 24, 2023)
 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value.”

OVERALL FINANCIAL RESULTS:
a4q22overallfinancialresul.jpg
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
Note: values may have been rounded


The following information was filed by Johnson Johnson (JNJ) on Tuesday, January 24, 2023 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Johnson Johnson's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Johnson Johnson.

Continue

Assess how Johnson Johnson's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Johnson Johnson's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Legal
Other
Filter Subcategory:
All
Product
Expense
Income
Shares
Earnings
Cash Flow
Geography
Debt
Dividend
Other
Inside Johnson Johnson's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income
Consolidated Statements Of Comprehensive Income (Parenthetical)
Consolidated Statements Of Earnings
Consolidated Statements Of Equity
Consolidated Statements Of Equity (Parenthetical)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) (Details)
Accumulated Other Comprehensive Income (Loss) (Tables)
Acquisitions And Divestitures
Acquisitions And Divestitures - Narrative (Details)
Borrowings
Borrowings (Tables)
Borrowings - Aggregate Maturities Of Long Term Obligations (Details)
Borrowings - Narrative (Details)
Borrowings - Schedule Of Long-Term Debt Instruments (Details)
Capital And Treasury Stock
Capital And Treasury Stock (Tables)
Capital And Treasury Stock - Changes In Treasury Stock (Details)
Capital And Treasury Stock - Narrative (Details)
Cash, Cash Equivalents And Current Marketable Securities
Cash, Cash Equivalents And Current Marketable Securities (Tables)
Cash, Cash Equivalents And Current Marketable Securities - Cash And Cash Equivalent Composition (Details)
Cash, Cash Equivalents And Current Marketable Securities - Contractual Maturities Of Available For Sale Securities (Details)
Common Stock, Stock Option Plans And Stock Compensation Agreements
Common Stock, Stock Option Plans And Stock Compensation Agreements (Tables)
Common Stock, Stock Option Plans And Stock Compensation Agreements - Narrative (Details)
Common Stock, Stock Option Plans And Stock Compensation Agreements - Schedule Valuation Assumptions (Details)
Common Stock, Stock Option Plans And Stock Compensation Agreements - Summary Of Options Outstanding (Details)
Common Stock, Stock Option Plans And Stock Compensation Agreements - Summary Of Restricted Share Units (Details)
Common Stock, Stock Option Plans And Stock Compensation Agreements - Summary Of Stock Option Activity (Details)
Earnings Per Share
Earnings Per Share (Tables)
Earnings Per Share - Narrative (Details)
Earnings Per Share - Reconciliation Of Basic Net Earnings Per Share To Diluted Net Earnings Per Share (Details)
Employee Related Obligations
Employee Related Obligations (Tables)
Employee Related Obligations - Employee Related Obligations (Details)
Employee Related Obligations - Narrative (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Financial Assets And Liabilities At Fair Value (Details)
Fair Value Measurements - Narrative (Details)
Fair Value Measurements - Schedule Of Derivatives Recorded In Consolidated Balance Sheets (Details)
Fair Value Measurements - Schedule Of Effect Of Derivatives Not Designated As Hedging Instruments (Details)
Fair Value Measurements - Schedule Of Effect Of Net Investment Hedges (Details)
Fair Value Measurements - Summary Of Activity Related To Equity Investments (Details)
Fair Value Measurements - Summary Of Derivative Activity (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Comparison Of Income Taxes At Statutory Rate And Company's Effective Tax Rate (Details)
Income Taxes - Narrative (Details)
Income Taxes - Provision For Income Taxes (Details)
Income Taxes - Summary Of Activity Related To Unrecognized Tax Benefits (Details)
Income Taxes - Temporary Differences And Carryforwards (Details)
Intangible Assets And Goodwill
Intangible Assets And Goodwill (Tables)
Intangible Assets And Goodwill - Estimated Amortization Of Intangible Assets (Details)
Intangible Assets And Goodwill - Goodwill (Details)
Intangible Assets And Goodwill - Narrative (Details)
Intangible Assets And Goodwill - Schedule Of Intangible Assets And Goodwill (Details)
International Currency Translation
International Currency Translation - Narrative (Details)
Inventories
Inventories (Details)
Inventories (Tables)
Legal Proceedings
Legal Proceedings (Details)
Pensions And Other Benefit Plans
Pensions And Other Benefit Plans (Tables)
Pensions And Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)
Pensions And Other Benefit Plans - Company' Retirement Plan Asset Allocation And Target Allocations (Details)
Pensions And Other Benefit Plans - Components Of Net Periodic Benefit Cost (Details)
Pensions And Other Benefit Plans - Information Related To The Benefit Obligation And The Fair Value Of Plan Assets (Details)
Pensions And Other Benefit Plans - Narrative (Details)
Pensions And Other Benefit Plans - Projected Future Benefit Payments From Company's Retirement And Other Benefit Plans (Details)
Pensions And Other Benefit Plans - Projected Future Minimum Contributions To The Company's U.S. And International Unfunded Retirement Plans (Details)
Pensions And Other Benefit Plans - Rates Used To Develop Actuarial Present Value Of Projected Benefit Obligation (Details)
Pensions And Other Benefit Plans - Schedule Of Defined Benefit Plans Disclosures (Details)
Pensions And Other Benefit Plans - Schedule Of Net Funded Status (Details)
Property, Plant And Equipment
Property, Plant And Equipment (Tables)
Property, Plant And Equipment - Narrative (Details)
Property, Plant And Equipment - Property, Plant And Equipment At Cost And Accumulated Depreciation (Details)
Restructuring
Restructuring (Tables)
Restructuring - Narrative (Details)
Restructuring - Summary Of Severance Charges And Associated Spending (Details)
Savings Plan
Savings Plan - Narrative (Details)
Segments Of Business And Geographic Areas
Segments Of Business And Geographic Areas (Tables)
Segments Of Business And Geographic Areas - Sales By Segment Of Business (Details)
Segments Of Business And Geographic Areas - Schedule Of Segment Reporting Information (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Estimated Useful Lives Of Assets (Details)
Summary Of Significant Accounting Policies - Narrative (Details)
Ticker: JNJ
CIK: 200406
Form Type: 10-K Annual Report
Accession Number: 0000200406-23-000016
Submitted to the SEC: Thu Feb 16 2023 4:01:53 PM EST
Accepted by the SEC: Thu Feb 16 2023
Period: Sunday, January 1, 2023
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/jnj/0000200406-23-000016.htm